These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 14557767)

  • 1. Insulin independence after conversion to tacrolimus and sirolimus-based immunosuppression in islet-kidney recipients.
    Toso C; Morel P; Bucher P; Mathe Z; Demuylder-Mischler S; Bosco D; Berney T; Oberholzer J; Shapiro J; Oberholzer J; Philippe J
    Transplantation; 2003 Oct; 76(7):1133-4. PubMed ID: 14557767
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of a sirolimus/tacrolimus-based immunosuppressive regimen on kidney function after islet transplantation.
    Andres A; Toso C; Morel P; Demuylder-Mischler S; Bosco D; Baertschiger R; Pernin N; Bucher P; Majno PE; Bühler LH; Berney T
    Transplant Proc; 2005 Mar; 37(2):1326-7. PubMed ID: 15848711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts.
    Gillard P; Ling Z; Mathieu C; Crenier L; Lannoo M; Maes B; Roep B; Gorus F; Pipeleers D; Keymeulen B
    Transplantation; 2008 Jan; 85(2):256-63. PubMed ID: 18212631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Islet of Langerhans allogeneic transplantation at the University of Geneva in the steroid free era in islet after kidney and simultaneous islet-kidney transplantations.
    Berney T; Bucher P; Mathe Z; Andres A; Bosco D; Mage R; Toso C; Oberholzer J; Becker C; Philippe J; Bühler L; Morel P
    Transplant Proc; 2004 May; 36(4):1121-2. PubMed ID: 15194390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impairment of renal function after islet transplant alone or islet-after-kidney transplantation using a sirolimus/tacrolimus-based immunosuppressive regimen.
    Andres A; Toso C; Morel P; Demuylder-Mischler S; Bosco D; Baertschiger R; Pernin N; Bucher P; Majno PE; Bühler LH; Berney T
    Transpl Int; 2005 Nov; 18(11):1226-30. PubMed ID: 16221151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved metabolic control and quality of life in seven patients with type 1 diabetes following islet after kidney transplantation.
    Cure P; Pileggi A; Froud T; Messinger S; Faradji RN; Baidal DA; Cardani R; Curry A; Poggioli R; Pugliese A; Betancourt A; Esquenazi V; Ciancio G; Selvaggi G; Burke GW; Ricordi C; Alejandro R
    Transplantation; 2008 Mar; 85(6):801-12. PubMed ID: 18360260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxicity?
    Desai NM; Goss JA; Deng S; Wolf BA; Markmann E; Palanjian M; Shock AP; Feliciano S; Brunicardi FC; Barker CF; Naji A; Markmann JF
    Transplantation; 2003 Dec; 76(11):1623-5. PubMed ID: 14702535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppression for pancreatic islet transplantation.
    Berney T; Buhler LH; Majno P; Mentha G; Morel P
    Transplant Proc; 2004 Mar; 36(2 Suppl):362S-366S. PubMed ID: 15041369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation.
    Roelen DL; Huurman VA; Hilbrands R; Gillard P; Duinkerken G; van der Meer-Prins PW; Versteeg-van der Voort Maarschalk MF; Mathieu C; Keymeulen B; Pipeleers DG; Roep BO; Claas FH
    Clin Exp Immunol; 2009 Apr; 156(1):141-8. PubMed ID: 19161445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience.
    Hirshberg B; Rother KI; Digon BJ; Lee J; Gaglia JL; Hines K; Read EJ; Chang R; Wood BJ; Harlan DM
    Diabetes Care; 2003 Dec; 26(12):3288-95. PubMed ID: 14633816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.
    Shapiro AM; Lakey JR; Ryan EA; Korbutt GS; Toth E; Warnock GL; Kneteman NM; Rajotte RV
    N Engl J Med; 2000 Jul; 343(4):230-8. PubMed ID: 10911004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achievement of insulin independence via pancreatic islet transplantation using a remote isolation center: a first-year review.
    Barshes NR; Lee T; Goodpasture S; Brunicardi FC; Alejandro R; Ricordi C; Soltes G; Barth M; Hamilton D; Goss JA
    Transplant Proc; 2004 May; 36(4):1127-9. PubMed ID: 15194393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus.
    Dean PG; Grande JP; Sethi S; Park WD; Griffin MD; Cosio FG; Larson TS; Stegall MD
    Transplantation; 2008 Apr; 85(8):1212-5. PubMed ID: 18431244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations of the female reproductive system in islet recipient receiving immunosuppression.
    Del Olmo Garcia MI; Lauriola V; Aracena AG; Messinger S; Corrales A; Ricordi C; Alejandro R
    Cell Transplant; 2011; 20(10):1649-51. PubMed ID: 21396172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus-atorvastatin drug interaction in the pancreatic islet transplant recipient.
    Barshes NR; Goodpastor SE; Goss JA
    Transplantation; 2003 Dec; 76(11):1649-50. PubMed ID: 14702546
    [No Abstract]   [Full Text] [Related]  

  • 17. Improved human pancreatic islet isolation for a prospective cohort study of islet transplantation vs best medical therapy in type 1 diabetes mellitus.
    Warnock GL; Meloche RM; Thompson D; Shapiro RJ; Fung M; Ao Z; Ho S; He Z; Dai LJ; Young L; Blackburn L; Kozak S; Kim PT; Al-Adra D; Johnson JD; Liao YH; Elliott T; Verchere CB
    Arch Surg; 2005 Aug; 140(8):735-44. PubMed ID: 16103282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Islet cell transplants. A new treatment could benefit some type 1 diabetics, but it's not a cure after all.
    Health News; 2004 Sep; 10(9):8-9. PubMed ID: 15597445
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful islet transplantation from the pancreata of non-heart-beating donors.
    Kenmochi T; Maruyama M; Saigo K; Akutsu N; Iwashita C; Otsuki K; Ito T; Suzuki A; Miyazaki M; Saito T
    Transplant Proc; 2008 Oct; 40(8):2568-70. PubMed ID: 18929803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.